Loading organizations...
Key people at Epitomee Medical.
Epitomee Medical was founded by Shimon Eckhouse (Co-Founder and Chairman of the Board).
Based in Caesarea, Israel, Epitomee Medical develops an ingestible, drug-free shapeshifting capsule that expands in the stomach to promote early fullness and reduce caloric intake for weight loss and obesity treatment. The company transitioned to the public markets through a $51 million initial public offering on the Tel Aviv Stock Exchange in 2021 at a $200 million pre-money valuation. Prior to going public, the medical device developer secured an $8 million equity financing round in 2019 at a $27 million valuation to advance its clinical trials and secure regulatory approvals. Epitomee Medical's major corporate shareholders include entities associated with prominent investors Idan Ofer and Udi Angel, while its public offering was underwritten by Leumi Partners and Barak Capital. The organization was originally founded as Tulip Medical in 2005 by Shimon Eckhouse and Doron Marco.
Key people at Epitomee Medical.
Epitomee Medical develops ingestible medical devices for treating chronic diseases, focusing on therapies delivered along the gastrointestinal tract via mechanosensory stimulation and controlled drug delivery.[1] The company targets the healthcare sector, particularly weight management and biologics delivery, serving patients and providers addressing chronic conditions.[1] Founded in 2005 and based in Caesarea Business Park, Israel, it went public on December 16, 2021, raising $8M total prior to IPO with a current market cap of 0.27B and stock price around 891.60.[1] Formerly known as Tulip Medical, it operates at the IPO stage, emphasizing innovative "screen and treat" point-of-care tools, though primary details center on its ingestible tech.[1]
Epitomee Medical, originally Tulip Medical, was founded in 2005 in Caesarea Business Park, Israel.[1] Specific founder details are not detailed in available sources, but the company emerged in the medtech space to pioneer ingestible devices for gastrointestinal therapy delivery.[1] Early evolution shifted from its prior name to Epitomee, culminating in an IPO on December 16, 2021, marking a pivotal moment after raising $8M in funding.[1] This trajectory reflects steady progress in Israel's robust medtech ecosystem, transitioning from development to public markets.
Epitomee Medical rides the wave of precision medtech and ingestible therapeutics, a trend accelerating with rising chronic disease prevalence like obesity and needing better drug delivery beyond pills or injections.[1] Timing aligns with post-2021 IPO markets favoring Israeli healthtech, amid global pushes for minimally invasive GI solutions amid aging populations and biologics boom. Market forces include competition from valve repair (NeoChord) or venous treatments (Varix), yet Epitomee's GI focus taps underserved segments.[1] It influences the ecosystem by validating ingestibles, inspiring similar innovations in Israel's Caesarea hub and broadening "screen and treat" adoption globally.
Epitomee Medical's ingestible platform positions it for expansion in weight management and beyond, potentially scaling via partnerships or new indications as GI biologics grow.[1] Trends like AI-enhanced delivery and personalized medicine will shape its path, with stock performance (891.60 price, 0.27B cap) signaling investor interest amid medtech rallies.[1] Influence may evolve through acquisitions or global trials, solidifying its role from niche developer to chronic care leader—echoing its origins in targeted, patient-centric innovation.[1]
Epitomee Medical was founded by Shimon Eckhouse (Co-Founder and Chairman of the Board).
